2CG Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)2.75K
Market Cap
€131.01K
Enterprise Value€311.41K
Total Cash (Recent Filing)€1.88K
Total Debt (Recent Filing)€57.14K
Price to Earnings (P/E)―
Beta-9.70
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding10,275,205
10 Day Avg. Volume2,755
30 Day Avg. Volume2,755
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.14
Price to Sales (P/S)0.00
P/FCF Ratio-8.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing Cash BurnA declining cash-burn rate is a constructive operating trend because it can extend financial runway and reduce the pace of funding needs. Although the company remains cash-flow negative, continued improvement would support more disciplined execution and could lessen dependence on frequent external financing over the next several quarters.
Earlier Loss ImprovementThe improvement in operating losses through 2024 indicates that expense control or operating discipline had produced some measurable progress before the latest deterioration. If management can restore that trajectory, it could provide a foundation for reducing losses and improving future financial resilience despite the absence of revenue.
Limited Absolute DebtLimited absolute debt reduces the direct burden of scheduled principal and interest obligations compared with a heavily indebted company. This offers some potential flexibility in capital allocation, although the benefit is constrained by deeply negative equity, declining assets, and the company’s broader financing dependence.
Bears Say
No Revenue BaseA sustained absence of reported revenue indicates that the company has not yet demonstrated commercial traction in the financial statements provided. Without an established top line, profitability depends on future execution and commercialization, leaving earnings visibility weak and making the business model difficult to self-fund.
Deeply Negative EquityDeeply negative equity means accumulated deficits outweigh the recorded asset base, leaving little balance-sheet protection for shareholders or creditors. This weak capitalization limits financial flexibility, heightens refinancing and going-concern risk, and increases the importance of securing additional funding to sustain operations.
Persistent Cash LossesPersistent negative operating and free cash flow show that the business has not generated enough cash to support itself through operations. Even with a generally lower burn rate, continued cash consumption requires outside financing and leaves the company vulnerable if funding becomes unavailable or execution remains delayed.
2CG FAQ
What was NanoSphere Health Sciences Inc’s price range in the past 12 months?
NanoSphere Health Sciences Inc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is NanoSphere Health Sciences Inc’s market cap?
NanoSphere Health Sciences Inc’s market cap is €131.01K.
When is NanoSphere Health Sciences Inc’s upcoming earnings report date?
NanoSphere Health Sciences Inc’s upcoming earnings report date is Nov 27, 2026 which is in 34 days.
How were NanoSphere Health Sciences Inc’s earnings last quarter?
NanoSphere Health Sciences Inc released its earnings results on Sep 01, 2026. The company reported -€0.008 earnings per share for the quarter.
Is NanoSphere Health Sciences Inc overvalued?
According to Wall Street analysts NanoSphere Health Sciences Inc’s price is currently Overvalued.
Does NanoSphere Health Sciences Inc pay dividends?
NanoSphere Health Sciences Inc does not currently pay dividends.
What is NanoSphere Health Sciences Inc’s EPS estimate?
NanoSphere Health Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoSphere Health Sciences Inc have?
NanoSphere Health Sciences Inc has 10,275,205 shares outstanding.
What happened to NanoSphere Health Sciences Inc’s price movement after its last earnings report?
NanoSphere Health Sciences Inc reported an EPS of -€0.008 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NanoSphere Health Sciences Inc?
Currently, no hedge funds are holding shares in DE:2CG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoSphere Health Sciences Inc
NanoSphere Health Sciences Inc. is a nano-biotechnology enterprise operating in the United States and Canada, specializing in the provision of biologically active compounds. The company's primary offering is the NanoSphere Delivery System, an innovative platform that harnesses nanotechnology to optimize the bio-delivery of supplements, nutraceuticals, and over-the-counter medications. This advanced technology serves diverse sectors including cannabis, pharmaceuticals, and animal health. Founded in 2005, the company maintains its headquarters in Vancouver, Canada.